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Abstract
OBJECTIVE: To identify the potential risk factors as-
sociated with Shenqifuzheng injection (SFI), a solu-
tion made of Dangshen (Radix Codonopsis) and
Huangqi (Radix Astragali Mongolici), for the timely
provision of information to regulatory authorities.
METHODS: A comprehensive analysis of the pro-
duction process, quality standards, pharmacology,
post-marketing clinical studies, and safety evalua-
tion using the primary literature of adverse reac-
tions (ADR), case analyses, and systematic reviews,
intensive hospital safety monitoring of post-mar-
keting drugs, and data provided by the hospital in-
formation system (HIS).
RESULTS: Sub-acute toxicity tests suggesting that
a dose of 15 mL/kg (concentrated solution) had
specific biological effects, whereas a smaller dose
engendered no observable effects. Long-term tox-
icity testing in domestic rabbits showed that after
SFI was administered for 90 days, the animals in
each dosing group showed no chronic toxic reac-
tions. Among 20 100 cases observed, the incidence
of an ADR was 1.85‰ . From March to November
2013, of the leading institutions and 22 sub-centers
involved in the post-marketing clinical safety inten-
sive hospital monitoring, 21 units completed 8484
cases of monitoring, and reported 23 cases of ad-
verse reactions. No damage to renal function was
found using SFI at a dosage and a treatment course
larger and longer than that recommended for the
adjuvant treatment of tumors. This could reduce
the mortality rate of admitted patients based on
the analysis of the data provided by the HIS. A total
of 16 clinical case reports of adverse reactions relat-
ed to SFI in 1999-2012 were obtained through liter-
ature retrieval. These reports contained informa-
tion concerning 17 cases, with adverse reaction
symptoms including thrombocytopenia, rash,
chills, feeling cold, palpitation, dyspnea, edema of a
lower extremity, palpebral edema, and superficial
vein inflammation, among others.
CONCLUSION: This study introduces "get full ac-
cess" to the flow of information on medicines re-
garding their ADR incidence rate and characteris-
tics and factors. It supports the safety of SFI for clini-
cal, research, and production uses based on objec-
498
JTCM |www. journaltcm. com August 15, 2014 |Volume 34 | Issue 4 |
Ai QH et al. / Review
tive, reliable, and scientific information to provide
safe medication.
© 2014 JTCM. All rights reserved.
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INTRODUCTION
Shenqifuzheng injection (SFI) is a solution of Dangsh-
en (Radix Codonopsis) and Huangqi (Radix Astragali
Mongolici) developed in 1987 from Traditional Chi-
nese Medicine (TCM) by a collaboration between Li-
min Pharmaceutical Factory of Livzon Pharmaceutical
Group Co., Ltd., and Dongzhimen Hospital of Beijing
University of Chinese Medicine. Its specification
claims that it strengthens the immune system and nour-
ishes vitality. It is used for lung and spleen deficiency
in TCM pattern differentiation. Its adverse reactions
include: (a) hyporrhea; (b) low-grade fever, stomatitis,
and drowsiness after medication; and (c) skin rash,
pain at the injection site, aversion to cold, chills, hyper-
pyrexia, vomiting, chest distress, and palpitation. This
medicine has been widely used as an adjuvant therapy
for tumor patients since it was marketed in 1999. The
company has conducted thorough studies on SFI, in-
cluding studies of its production process, quality stan-
dards and pharmacology, post-marketing clinical stud-
ies, and post-marketing safety evaluation for continu-
ously improving its efficacy, safety and quality control.
QUALITY CONTROL
Raw medicine quality
Livzon Pharmaceutical Group Co., Ltd., has estab-
lished the Dangshen (Radix Codonopsis) and Huangqi
(Radix Astragali Mongolici) production bases in Longxi,
Gansu Province and Hunyuan, Shanxi Province, to
plant, harvest, process and store the medicinal materi-
als required to produce SFI in strict compliance with
good agriculture practise (GAP). The production pipe-
line is well controlled to meet the goals of high quality,
safety, stability and control over the raw medicinal ma-
terials. All raw materials for SFI come from GAP-certi-
fied bases. Each batch of medicinal material is tested
for conformity with the internal control standard of en-
terprise before being put into production to guarantee
product quality. Internationally recognized "genetic
fingerprint" and "chemical fingerprint" processes are
used to control the provenance and raw medicinal qual-
ity to realize standardized production of SFI.
Production process good laboratory practice (GLP)
The process of SFI production incorporates multiple
production technologies, including multifunctional dy-
namic extraction, low-temperature membrane concen-
tration, low-temperature alcohol precipitation,
high-speed centrifugal separation, and multistage mi-
croporous membrane separation. The company re-
serves samples from each batch of marketed products
for monitoring to identify stability problems relating
to medicine production, and ensure that the final prod-
uct can meet the requirements of standard quality un-
der the indicated storage conditions. Each year at least
three batches of reserved samples are inspected for
trend analysis of the inspection data, the preparation of
reports on its continuous stability inspection, and time-
ly reporting to relevant authorities. In the case of any
result that has been confirmed not to conform to the
quality standards or any major adverse trend, risk evalu-
ation procedures are initiated. Such evaluations focus
on quality risks from the marketed products, and
where necessary, the products concerned are recalled.
The investigation results and measures taken are report-
ed to local drug regulators.
NONCLINICAL SAFETY AND
PHARMACOLOGICAL STUDIES
In 1987, Livzon Pharmaceutical Group Co., Ltd., en-
trusted a series of pharmacological and toxicity tests to
the Basic Laboratory of Dongzhimen Hospital of Bei-
jing University of Chinese Medicine, including acute
toxicity testing, sub-acute toxicity testing, long-term
toxicity testing, and general pharmacological testing.
From September to November 2007, the company
conducted special safety tests concerning anaphylaxis,
hemolysis, local irritation, vascular irritation, and ab-
normal toxicity under GLP testing conditions at the
Guangzhou Institute of Pharmaceutical Industry.
From April to June, 2010, the company conducted pas-
sive cutaneous anaphylaxis testing on rats under GLP
testing conditions at the Guangzhou Institute of Phar-
maceutical Industry. The results are as follows:
Acute toxicity test
Different doses were arranged according to Karber's
Method and administered to rats through their caudal
veins. Karber's method required determination of the
median lethal dose, with standard deviation of the
probability table to identify the number, with a final
calculation of the 95% confidence limit. The median
lethal dose in female mice was: the same amount of
crude drug Dangshen (Radix Codonopsis) and Huangqi
(Radix Astragali Mongolici) (30.90±2.90) g/kg. The me-
dian lethal dose in male mice was: the same amount of
crude drug Dangshen (Radix Codonopsis) and Huangqi
(Radix Astragali Mongolici) (31.92±3.10) g/kg; 95% fe-
male mice confidence limit: (30.90 ± 1.36) g/kg, male
mice 95% confidence limits: (31.90±0.44) g/kg.
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Sub-acute toxicity test
In this test, the eligible dogs were divided into three
groups: the high dosing group (250 mL SFI was con-
centrated to 20 mL before administration, and the
dose was 15 mL·kg ﹣ 1·w ﹣ 1), the low dosing group
(250 mL SFI was concentrated to 20 mL before admin-
istration and the dose was 10 mL·kg﹣1·w﹣1), and the
normal control group (normal saline, 15 mL·kg﹣1·w﹣1).
The administration route was intravenous. The admin-
istration regimen lasted for 100 days in total. Changes
in indicators including red blood cell (RBC), white
blood cell (WBC), hemichrome (Hb), hematocrit
(HCT), blood platelet (PLT), blood urea nitrogen
(BUN), glutamate pyruvate transaminase (GPT), glu-
tamic oxaloacetic transaminas (GOT), alkaline phos-
phatase, acid phosphatase, myocardial zymogram and
leukocyte differential count were tested after the 50th
and 100th days. The dogs were weighed once every 20
days. The appearance and behavior changes in the dogs
were observed each day.
The high dosing group was administered the drug for
100 consecutive days. In this group, the percentages of
body weight growth and the levels of alkaline phospha-
tase, acid phosphatase, and myocardial zymogram of
the dogs were not statistically different compared with
their own baseline values; the levels of urea nitrogen
and transaminase, and heart, liver and kidney weights
increased somewhat compared with the baseline values.
On examination of pathological sections, Dog No. 1
showed some plasmocyte and lymphocyte infiltration
in the liver portal area. Dog No. 1 and 3 indicated
some monocyte infiltration in their interstitial tissues.
Dog No. 1, 3, and 4 occasionally showed epithelial vac-
uolar degeneration in their kidney tubules. Examina-
tion of other indicators and pathological sections
showed no abnormal changes. The changes in the
above indicators may be associated with excessively
large dosing volumes. The low dosing group was ad-
ministered the drug for 100 days. In this group, the
percentages of body weight growth, the levels of urea
nitrogen, transaminase, acidic enzyme, and alkali en-
zymes, and tissue weights and hemocyte differential
counts of the dogs were not statistically significantly
changed (P>0.05) compared with their own baseline
values. On pathological examination, except for Dog
No. 2, which displayed some plasmocyte and lympho-
cyte infiltration in its liver portal area, as well as some
karyocyte infiltration in its interstitial tissue, any exami-
nation indicator of the dogs was within the normal
range. This indicated that there were no adverse conse-
quences in the low dosing group administrated SFI at a
dose of 10 mL/kg (concentrated solution). Besides the
intra-group comparisons, the small and high dosing
groups were separately compared with the normal con-
trol group. The levels of urea nitrogen and transami-
nase in the hearts, livers, or kidneys of the dogs in the
two dosing groups were higher than in the control
group. On pathological examination, the livers and kid-
neys of the dogs in the high dosing group also showed
lesions to different degrees, suggesting that the dose of
15 mL/kg (concentrated solution) had certain adverse
consequences, whereas the low dose did not.
Long-term toxicity: tests in domestic rabbits: the ani-
mals were divided into low, medium and high dosing
groups. The doses for the three groups were equal to
3.6, 5.25 and 8.9 kg/mL of the median lethal dose for
rabbits through intravenous (IV) injection, respective-
ly, and equivalent to 8.0, 5.4, and 3.2 times the nor-
mal human dose. Also, a normal control group (nor-
mal saline, 2.5 mL/kg) was used in this test. The ad-
ministration route was intravenous injection; the rab-
bits were administered once a day for 90 days, during
which one re-examination was conducted. After all in-
dicators including the hemogram, liver function, renal
function and electrocardiogram tests were re-examined
on the 90th day, the rabbits were sacrificed, and their
kidneys, hearts, livers, spleens, lungs and adrenal gland
tissues were immediately harvested.
After SFI were administered for 90 days, the rabbits
from each dosing group grew well. Their cognitive ac-
tivities were normal, and no rabbits died or showed
any abnormal reactions. Weight gain was observed in
the animals from each dosing group of SFI and was di-
rectly proportional to the dose. Each dosing group
showed no obvious changes in RBC, WBC, Hb, GPT,
BUN, electrocardiogram and heart rate compared with
the control group. One case in each group showed in-
flammatory reactions in the liver and lungs, but there
were no abnormal changes in the heart, spleen and ad-
renal gland. In conclusion, after SFI was administered
for 90 days, the animals in each dosing group showed
no chronic toxic reaction.
Test in dogs
The animals were divided into three groups: the high
dosing group (92.3 g crude drug·kg﹣ 1·d﹣ 1, IV) and
low dosing group (49.2 g crude drug·kg﹣1·d﹣1, IV) of
SFI, and the blank control group (15 mL·kg﹣ 1·d﹣ 1,IV) of normal saline. The doses for the high dosing
group and low dosing group were equivalent to 230
and 120 times the normal human dose (20 g crude
drug, 250 mL·d﹣1·50 kg﹣1), respectively.
After SFI was administered for 90 days, no toxic reac-
tion associated with the drug was observed, and all
findings including symptoms, hematology, blood bio-
chemistry, body weight, electrocardiogram, general sys-
tem autopsy and histopathologic examination results
showed that there were no significant differences be-
tween the high and low dosing groups and the blank
control group. Two weeks after drug discontinuance,
there continued to be no gross pathology.
General pharmacological test
Tests in domestic rabbits: there were no abnormal
changes in the activities or behaviors of domestic rab-
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bits within 30 min after they were administered SFI.
The respiration and electrocardiograms of the domes-
tic rabbits were not abnormal before or after injection.
The blood pressures of the domestic rabbits dropped
and respiratory amplitudes increased at the moment of
intravenous injection of SFI into the ear veins of the
animals, which generally recovered within 1 min. In
the case of slow administration or duodenal administra-
tion, no obvious changes were observed in the dosing
group compared with the control group. A standard Ⅱ
electrocardiogram, heart sound, and heart rate showed
no difference compared with the control group, which
suggested that different doses of SFI had no significant
impact on respiration, blood pressure, heart sound,
electrocardiography, or heart rate in domestic rabbits.
Tests in mice: There was no abnormal reaction within
30 min after administration of SFI in the mouse. The
cognition and behaviors of the mice were normal, and
the body temperature was the same as before adminis-
tration. SFI had no significant impact on liver func-
tion, renal function, or hemography in mice.
Pharmacological re-evaluation study
Antineoplastic pharmacodynamics study: tests in mice
showed that when SFI was combined with chemothera-
peutics, its efficacy was improved and synergistic ef-
fects were produced by inhibiting tumor cell growth
and enhancing body disease resistance and immunolog-
ic function. There was an obvious protective effect
against decreased immunologic function in mice associ-
ated with chemotherapy and tumor-induced consump-
tion.
Cardiovascular pharmacodynamics study
Tests in rats showed that SFI significantly reduced the
area of myocardial infarction and infarct weight, pro-
duced an effect similar to that of the control drugs Dil-
tiazem Hydrochloride injection and Danshen solution,
obviously decreased malondialdehyde content, and had
obvious protective effects on myocardial ischemia re-
perfusion injury. Furthermore, SFI significantly im-
proved acute myocardial ischemia of rats in the trials.
Hemodynamic study: tests in mice, rats, and domestic
rabbits indicated that SFI could significantly increase
coronary blood-flow volume of ischemic heart and nu-
tritional blood flow of cardiac muscle, and obviously
improved diastolic function of acute anoxic heart
chamber. Moreover, it inhibited platelet aggregation
and thrombogenesis, and reduced blood viscosity.
Antidiabetic pharmacodynamic study
After diabetic rats were administered SFI, the levels of
serum BUN and Cr decreased to different degrees and
increased in blood pressure. Plasma angiotensin Ⅱ
markedly weakened, and the range of c-fos cancer gene
protein expression decreased. Significant differences
were observed in the dosing groups compared with the
control group, whereas the level of blood glucose did
not change considerably.
POST-MARKETING CLINICAL
SAFETY STUDIES
The effectiveness of the re-evaluation is an important
part of TCM listed after the evaluation, including the
re-evaluation of clinical syndromes that adapt to the
dose and duration of treatment, ensuring drug safety is
an important prerequisite.2 At the same time, we be-
lieve that the listing of clinical re-evaluation of Chinese
medicine is based on TCM theory, and the emphasis
on the role of the body's overall response to the medi-
cine.3
Post-marketing intensive monitoring
Guangdong Pharmacological Society was entrusted
with post-marketing intensive monitoring study of SFI
in 2007. Their results showed that among 20 100 cases
observed, the incidence of adverse drug reaction
(ADR) was 1.85‰ , 27 cases had "slight" adverse reac-
tions/events, and 10 cases displayed "moderate" ad-
verse reactions/events. There were no severe adverse re-
actions/events. The adverse reactions were dominated
by damage to skin and its appendages; major clinical
symptoms included rash (12 cases) and injection site
pain (6 cases), with a cumulative frequency of 48.65%.
These symptoms occurred mainly within 1 day follow-
ing administration (94.59%), and they all healed or im-
proved.
Post-marketing Phase-Ⅳ study
From December 2009 to January 2011, Guang
An'men Hospital of the China Academy of Chinese
Medical Sciences was entrusted with a "Randomized,
Double-blind, Multi-site Clinical SFI-Placebo trial for
evaluating its efficacy and safety in improving symp-
toms and life quality of patients with non-small cell
lung cancer undergoing chemotherapy (lung and
spleen deficiency)" and "randomized, double-blind,
multi-site clinical trial with SFI as a positive control
for evaluating the efficacy and safety of SFI in improv-
ing the symptoms and quality of life of patients with
Gastric Cancer undergoing chemotherapy (lung and
spleen deficiency)". Study results showed that in 339
cases where SFI provided adjuvant treatment, SFI had
definite efficacy in treating the patients with symptoms
such as fatigue, lack of energy, reluctance to speak, and
spontaneous perspiration and dizziness that occurred
along with lung cancer (267 cases) and gastric cancer
(72 cases), with the efficacy in the dosing groups better
than that in the positive control and placebo group. At
the therapeutic dose, there were no severe adverse reac-
tions.
Registry-based post-marketing clinical safety
monitoring
From December, 2012, the Institute of Basic Research
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in Clinical Medicine, China Academy of Chinese Med-
ical Sciences was entrusted to conduct a post-market-
ing safety re-evaluation study of this drug. Currently,
this project has passed the review conducted by the
Ethics Committee of the Institute of Basic Research in
Clinical Medicine and its international protocol regis-
tration has been completed in clinicaltrials.gov (ID:
NCT01812875). Meanwhile, we have also completed
a safety literature study concerning this drug, its sys-
tematic evaluation study, and safety, efficacy, and eco-
nomics studies based on hospital information system
(HIS) data, as well as a safety study based on spontane-
ous reporting system (SRS) data. Clinical safety studies
focused on monitoring the registration type of the hos-
pital have achieved progress. Leading institutions and
22 sub-centers have participated in the post-marketing
clinical safety intensive hospital monitoring. According
to the program, clinical monitoring for 30 000 cases
will be completed by 2015. SFI post-marketing clinical
safety studies focused on monitoring the hospital had a
lead unit and 21 sub-centers that participated, with
plans to complete the clinical monitoring of 30 000
cases in 2015. From March to November 2013, these
21 units completed 8484 cases of monitoring and
found 23 cases of adverse reactions. To further
strengthen quality control, the research team will orga-
nize experts in December, on which a lead unit and
two sub-centers conducted a field inspection, inspec-
tors including acquisition monitoring hospitals and re-
searchers' qualifications, monitoring mode, biological
samples, HIS database, monitoring tables and original
information.
HIS data analysis
Based on HIS data and the LIS database concerning in-
patients in 20 Class Ⅲ Grade A (Top Grade) hospitals
nationwide, the data from the basic information form,
Western/TCM diagnosis information form, doctor's
advice information form and physicochemical indica-
tor form were analyzed. With descriptive statistics and
statistical modeling, total-population descriptive statis-
tical analysis and medicine specification, data on in-
tended populations, dead populations, medication regi-
mens, suspected anaphylaxis and drug safety were ana-
lyzed. Demographic characteristics of patients adminis-
tered SFI in 20 hospitals, the dosage of administration,
dosing regimens, and medication safety were fully pro-
vided. For example, (a) most of the patients were be-
tween the ages of 46 and 65, accounting for 65.32% of
the study population. The male to female ratio was
1.57∶1. Patients at the time of admission to the hospi-
tals were mainly under a general diseased condition,
such as postoperative patients with lung cancer or oth-
er tumors,diabetesand coronary disease, and patients
under critical condition only accounted for 7.37%. Pa-
tients were mainly admitted to oncology departments,
surgical departments, kidney disease departments, and
respiratory departments, among others. Inpatients
were mainly those covered by medical insurance. The
single maximum dose was 250 mL, accounting for
98.39% of the total patients. The treatment course
mostly lasted for 1-3 days, accounting for 37% , fol-
lowed by 4-7 days, accounting for 31% . (b) Drugs
combined with SFI for treating lung cancer where SFI
provided adjuvant treatment mainly included Aidi in-
jection, hexadecadrol, ambroxol and Compound Radix
Sophorae Flavescentis Injection. (c) Drugs combined
with SFI for treating gastric cancer where SFI provided
adjuvant treatment mainly included omeprazole, oxali-
platin, hexadecadrol and fluorouracil. (d) Comparisons
between the group administrated a dose higher than
the commended dose in the specification of SFI and
the normal dosing group showed no abnormal changes
in renal function.4 (e) When SFI provided adjuvant
treatment for tumors, it reduced the mortality rate of
inpatients.5
Literature review
Analysis of adverse reaction cases reported in literature:
a total of 16 clinical case reports of adverse reactions
concerning SFI in 1999-2012 were obtained through
literature retrieval. These reports contained informa-
tion concerning 17 cases. There were no deaths in
these 17 cases, but six cases showed severe adverse reac-
tions, with one case involving anaphylactic shock, and
five cases involving severe anaphylactoid reaction. In
these 17 cases, the most delayed adverse reaction oc-
curred after a 7-day continuous transfusion, and the
earliest one occurred 2 min after the beginning of trans-
fusion. Adverse reaction symptoms concerning SFI dis-
covered in the literature mainly included thrombocyto-
penia, rash, chills, feeling cold, palpitation, dyspnea,
edema of a lower extremity, palpebral edema, and su-
perficial vein inflammation.
Systematic review of SFI
Studies of SFI for heart failure: a systematic review and
Meta-analysis6 using existing clinical data show that in
combination with conventional Western medicines, ad-
ministration of SFI could improve clinical effectiveness
for the treatment of cardiac failure; however, because
of the studies with relatively low quality included in
this systematic review, and the increased risk for creat-
ing bias in the conclusion of this systematic review,
more high-quality clinical trials are necessary for vali-
dating the efficacy and safety of SFI in treating cardiac
failure.
CONCLUSION
In summary, SFI was prepared with Dangshen (Radix
Codonopsis) and Huangqi (Radix Astragali Mongolici),
which are Chinese herbal medicines used to strengthen
immune functions. The active ingredients extracted
from them were flavonoid glycoside and saponin. SFI
502
JTCM |www. journaltcm. com August 15, 2014 |Volume 34 | Issue 4 |
Ai QH et al. / Review
helps improve radiotherapy and chemotherapy efficacy
in patients7 and improves immune functions and quali-
ty of life in patients with a Qi deficiency pattern.8
With the above studies, we have completed one HIS
statistical analysis report on SFI, one systematic review
report, and one ADR analysis report on SFI, and have
published five academic papers concerning this drug.
We intend to audit hospital intensive monitoring of
the clinical safety of SFI in 2014. This study adopted
the integrated study mode of combining active moni-
toring with passive monitoring, prospective study with
retrospective study, and literature study with actual ef-
fect study. The goal was to comprehensively examine
the ADR incidence, characteristics and influencing fac-
tors, and form a body of evidence regarding safety to
provide an objective, reliable, and scientific basis for re-
search into the safe clinical application and production
of SFI.
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